Johnson & Johnson Innovative Medicine
Johnson & Johnson Innovative Medicine
The Janssen Pharmaceutical Companies of Johnson & Johnson is now J&J Innovative Medicine.
Titusville Campus
1125 Trenton-Harbourton Road
Titusville, NJ 08560
Raritan Campus
1000 U.S. Route 202 South
Raritan, NJ 08869
Horsham Campus
800 Ridgeview Drive
Horsham, PA 19044
Phone: 1-800-JANSSENWebsite: https://www.janssen.com/us/Careers: www.janssen.com/us/careers
Latest news
- Rybrevant (amivantamab-vmjw) Plus Standard of Care Approved in the U.S. as First and Only Targeted Regimen to Cut Risk of Disease Progression by More Than Half in Second-Line EGFR-Mutated Advanced Lung Cancer
19 September 2024 - Tremfya (guselkumab) Receives U.S. FDA Approval for Adults with Moderately to Severely Active Ulcerative Colitis
13 September 2024 - Johnson & Johnson Seeks First Approval of Nipocalimab to Treat Broadest Population Living with Antibody Positive Generalized Myasthenia Gravis
29 August 2024 - FDA Approves Rybrevant (amivantamab-vmjw) Plus Lazcluze (lazertinib) for Patients with EGFR-Mutated Advanced Lung cancer
20 August 2024 - Groundbreaking Nipocalimab Study of Pregnant Individuals at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn Published in The New England Journal of Medicine
7 August 2024 - Darzalex Faspro (daratumumab and hyaluronidase-fihj)-Based Quadruplet Regimen Approved in the U.S. for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible
30 July 2024 - FDA Converts Tuberculosis Treatment Sirturo to Traditional Approval
21 June 2024 - Late-Breaking Results Show Nipocalimab Significantly Improves Sjögren’s Disease Activity in a Phase 2 Study
15 June 2024 - Late-Breaking Results from PALOMA-2 Study of Subcutaneous Amivantamab in Combination with Lazertinib Show Clinically Meaningful Antitumor Response and Improved Safety Profile in Patients with EGFR-Mutated Non-Small Cell Lung Cancer
3 June 2024 - Phase 2 data for Erleada plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer results published
3 May 2024
Drugs Associated with Johnson & Johnson Innovative Medicine
Johnson & Johnson Innovative Medicine manufactures, markets and/or distributes more than 50 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Akeega
Generic name: abiraterone/niraparib Drug class: antineoplastic combinations |
||
|
Balversa
Generic name: erdafitinib Drug class: multikinase inhibitors |
1 review | 10 / 10 |
|
Carvykti
Generic name: ciltacabtagene autoleucel Drug class: miscellaneous antineoplastics |
||
|
Concerta
Generic name: methylphenidate Drug class: CNS stimulants |
400 reviews | 6.9 / 10 |
|
Darzalex
Generic name: daratumumab Drug class: CD38 monoclonal antibodies |
5 reviews | 7.8 / 10 |
|
Darzalex Faspro
Generic name: daratumumab/hyaluronidase Drug class: CD38 monoclonal antibodies |
1 review | 9.0 / 10 |
|
Ditropan XL
Generic name: oxybutynin Drug class: urinary antispasmodics |
4 reviews | 9.5 / 10 |
|
Edurant
Generic name: rilpivirine Drug class: NNRTIs |
||
|
Elmiron
Generic name: pentosan polysulfate sodium Drug class: miscellaneous genitourinary tract agents |
93 reviews | 7.3 / 10 |
|
Erleada
Generic name: apalutamide Drug class: antiandrogens, hormones/antineoplastics |
16 reviews | 7.4 / 10 |
|
Haldol
Generic name: haloperidol Drug class: miscellaneous antipsychotic agents |
64 reviews | 4.6 / 10 |
|
Haldol Decanoate
Generic name: haloperidol Drug class: miscellaneous antipsychotic agents |
3 reviews | 3.3 / 10 |
|
Imbruvica
Generic name: ibrutinib Drug class: BTK inhibitors |
57 reviews | 6.3 / 10 |
|
Intelence
Generic name: etravirine Drug class: NNRTIs |
2 reviews | 8.0 / 10 |
|
Invega
Generic name: paliperidone Drug class: atypical antipsychotics |
209 reviews | 4.8 / 10 |
|
Invega Hafyera
Generic name: paliperidone Drug class: atypical antipsychotics |
1 review | 10 / 10 |
|
Invega Sustenna
Generic name: paliperidone Drug class: atypical antipsychotics |
178 reviews | 3.7 / 10 |
|
Invega Trinza
Generic name: paliperidone Drug class: atypical antipsychotics |
31 reviews | 6.3 / 10 |
|
Invokamet
Generic name: canagliflozin/metformin Drug class: antidiabetic combinations |
2 reviews | 2.5 / 10 |
|
Invokamet XR
Generic name: canagliflozin/metformin Drug class: antidiabetic combinations |
||
|
Invokana
Generic name: canagliflozin Drug class: SGLT-2 inhibitors |
231 reviews | 5.8 / 10 |
|
Opsumit
Generic name: macitentan Drug class: agents for pulmonary hypertension |
10 reviews | 8.2 / 10 |
|
Opsynvi
Generic name: macitentan/tadalafil Drug class: agents for pulmonary hypertension |
||
|
Ponvory
Generic name: ponesimod Drug class: selective immunosuppressants |
||
|
Prezcobix
Generic name: cobicistat/darunavir Drug class: antiviral combinations |
3 reviews | 4.0 / 10 |
|
Prezista
Generic name: darunavir Drug class: protease inhibitors |
3 reviews | 7.7 / 10 |
|
Procrit
Generic name: epoetin alfa Drug class: recombinant human erythropoietins |
5 reviews | 3.8 / 10 |
|
Remicade
Generic name: infliximab Drug class: antirheumatics, TNF alfa inhibitors |
200 reviews | 7.1 / 10 |
|
Risperdal
Generic name: risperidone Drug class: atypical antipsychotics |
228 reviews | 6.0 / 10 |
|
Risperdal Consta
Generic name: risperidone Drug class: atypical antipsychotics |
14 reviews | 6.0 / 10 |
|
Rybrevant
Generic name: amivantamab Drug class: miscellaneous bispecific antibodies |
2 reviews | 9.0 / 10 |
|
Simponi
Generic name: golimumab Drug class: TNF alfa inhibitors |
114 reviews | 6.2 / 10 |
|
Simponi Aria
Generic name: golimumab Drug class: TNF alfa inhibitors |
27 reviews | 5.6 / 10 |
|
Sirturo
Generic name: bedaquiline Drug class: diarylquinolines |
||
|
Sporanox
Generic name: itraconazole Drug class: azole antifungals |
17 reviews | 8.4 / 10 |
|
Spravato
Generic name: esketamine Drug class: miscellaneous antidepressants |
109 reviews | 6.2 / 10 |
|
Stelara
Generic name: ustekinumab Drug class: interleukin inhibitors |
222 reviews | 7.6 / 10 |
|
Symtuza
Generic name: cobicistat/darunavir/emtricitabine/tenofovir alafenamide Drug class: antiviral combinations |
8 reviews | 8.2 / 10 |
|
Talvey
Generic name: talquetamab Drug class: bispecific T-cell engagers (BiTE) |
||
|
Tecvayli
Generic name: teclistamab Drug class: bispecific T-cell engagers (BiTE) |
1 review | 10 / 10 |
|
Topamax
Generic name: topiramate Drug class: carbonic anhydrase inhibitor anticonvulsants |
593 reviews | 6.1 / 10 |
|
Tracleer
Generic name: bosentan Drug class: agents for pulmonary hypertension |
4 reviews | 9.5 / 10 |
|
Tremfya
Generic name: guselkumab Drug class: interleukin inhibitors |
79 reviews | 7.0 / 10 |
|
Uptravi
Generic name: selexipag Drug class: agents for pulmonary hypertension |
21 reviews | 5.4 / 10 |
|
Veletri
Generic name: epoprostenol Drug class: agents for pulmonary hypertension |
2 reviews | 7.5 / 10 |
|
Ventavis
Generic name: iloprost Drug class: agents for pulmonary hypertension |
||
|
Vermox
Generic name: mebendazole Drug class: anthelmintics |
1 review | 8.0 / 10 |
|
Xarelto
Generic name: rivaroxaban Drug class: factor Xa inhibitors |
194 reviews | 5.5 / 10 |
|
Yondelis
Generic name: trabectedin Drug class: alkylating agents |
||
|
Zavesca
Generic name: miglustat Drug class: miscellaneous metabolic agents |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||